Adma Biologics (ADMA) Q3 Earnings Match Estimates

Core Viewpoint - Adma Biologics reported quarterly earnings of $0.16 per share, matching the Zacks Consensus Estimate, and showing a year-over-year increase from $0.15 per share [1] Financial Performance - The company posted revenues of $134.22 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.17%, and up from $119.84 million a year ago [2] - Over the last four quarters, Adma Biologics has surpassed consensus revenue estimates three times [2] Stock Performance - Adma Biologics shares have declined approximately 14.7% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $139.8 million, and for the current fiscal year, it is $0.57 on revenues of $506.7 million [7] - The trend of earnings estimate revisions for Adma Biologics was mixed prior to the earnings release, which may influence future stock movements [5][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]